GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Altimmune Inc.
Altimmune is a biotech company whose shares have experienced ups and downs on news of the development of a COVID-19 vaccine and then an obesity treatment. Its price chart is a prime example of the high volatility and speculation in the biotech sector.
Share prices of companies in the market segment - Pharma metabolism
Altimmune is a biopharmaceutical company developing treatments for obesity and liver disease, including peptide analogs of GLP-1 and nasal vaccines. We've classified it in the "Pharma Metabolism" segment. The chart below shows the overall dynamics in this hot pharmaceutical sector, where the battle for the obesity market is underway.
Broad Market Index - GURU.Markets
Altimmune is a biopharmaceutical company developing treatments for obesity and liver disease. As a component of the GURU.Markets index, it represents one of the most promising biotech sectors. The chart below represents the entire market. See how Altimmune shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ALT - Daily change in the company's share price Altimmune Inc.
Altimmune, a biopharmaceutical company, has seen price fluctuations reflect the dynamics of the weight-loss drug sector. Change_co demonstrates high sensitivity to clinical trial results. This indicator is an important component of formulas on System.GURU.Markets that assess volatility in the biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Altimmune, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ALT, which focuses on treating obesity and liver disease, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Altimmune is a biopharmaceutical company developing drugs to treat obesity and liver disease. This is one of the hottest and most volatile areas in pharmaceuticals. The chart below reflects the average fluctuations in this industry, providing context for evaluating Altimmune shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Altimmune Inc.
For Altimmune, Inc., year-over-year performance is a story of the race in the multibillion-dollar weight-loss drug market. Its 12-month market cap is crucially dependent on the clinical trial data of its candidate. Any news about its efficacy and safety could trigger explosive growth or collapse, as the company competes with giants like Novo Nordisk and Eli Lilly.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Altimmune, Inc. is a clinical-stage biotech developing drugs for the treatment of obesity and liver disease. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its drugs in this highly competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Altimmune is one of the hottest stories in biotech, focused on developing anti-obesity drugs. Its stock price has nothing to do with the economy, but is driven by news of clinical trials. The chart reflects investors' high hopes for a new blockbuster.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Altimmune Inc.
Altimmune, a biopharmaceutical company, has a speculative market cap. The monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for obesity and liver disease, which represent a huge but highly competitive market.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Altimmune is a biotech company developing drugs to treat obesity and liver disease. It is a participant in a highly competitive race in one of the hottest areas of pharmaceuticals. The biotech sector's market cap, particularly in the metabolic disease segment, reflects the enormous expectations and risks associated with this therapeutic area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Altimmune develops drugs to treat obesity and liver disease. The company is at the center of one of the hottest topics in pharmaceuticals. Its shares are extremely volatile, moving not with the market, but on news of trial results and the actions of competitors like Novo Nordisk and Eli Lilly. The chart reflects this intense race.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Altimmune Inc.
Altimmune, a biotech company developing drugs to treat obesity and liver disease, operates in one of the most competitive markets. Its weekly stock price is a direct response to clinical trial results (both its own and those of its competitors), creating extreme volatility.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Biotech companies working on obesity treatments, like Altimmune, are at the center of one of the hottest topics in pharmaceuticals. The entire sector is driven by news of clinical trials. The chart below illustrates this general excitement. It allows one to assess how promising the market considers Altimmune's technology compared to the market giants.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Altimmune is a clinical-stage biotech developing drugs to treat obesity and liver disease. This is a hot topic in the pharmaceutical industry. The chart shows how its shares rise and fall on trial news, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
ALT - Market capitalization of the company Altimmune Inc.
Altimmune's market capitalization is a financial expression of the hopes for its drugs for treating obesity and liver disease. Its high volatility on the chart is a direct reaction from investors to the clinical trial data. The company's value is a bet on its candidate's ability to compete in one of the hottest markets in modern pharmaceuticals.
ALT - Share of the company's market capitalization Altimmune Inc. within the market segment - Pharma metabolism
Altimmune is a biopharmaceutical company developing treatments for obesity and liver disease. In the hot weight-loss drug segment, its market cap reflects investor hopes that its candidate will compete with blockbusters from Novo Nordisk and Eli Lilly. Its market cap is a rollercoaster, driven by clinical trial data.
Market capitalization of the market segment - Pharma metabolism
This chart shows the total value of the entire biotech sector focused on treating metabolic diseases. For Altimmune, which is developing an obesity drug, this line represents a gigantic "prize fund." The chart's dynamics, fueled by the success of its competitors, demonstrate the multi-billion-dollar and competitive market the company is targeting.
Market capitalization of all companies included in a broad market index - GURU.Markets
Altimmune develops drugs to treat obesity and liver disease. Its market capitalization reflects its continued commitment to solving one of the most pressing healthcare challenges of the 21st century. Its market share represents a significant investment in the fight against obesity.
Book value capitalization of the company, segment and market as a whole
ALT - Book value capitalization of the company Altimmune Inc.
Altimmune develops drugs to treat obesity and liver disease. Its book value represents its financial resources for research. It consists of cash that allows the company to conduct expensive clinical trials of its candidates. How has this capital changed in the race for the next blockbuster? The chart below shows.
ALT - Share of the company's book capitalization Altimmune Inc. within the market segment - Pharma metabolism
Altimmune, Inc. develops therapies for obesity and liver disease. Its scientific ambitions require a resource base: laboratories for developing peptide drugs and conducting preclinical studies. The chart shows the company's share of the physical R&D infrastructure in this highly competitive biopharma segment.
Market segment balance sheet capitalization - Pharma metabolism
Altimmune, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Altimmune's balance sheet isn't its factories, but its scientific platform and clinical trial data for drugs for obesity and liver disease. The company's core assets are its intellectual property. The chart shows how this intangible but potentially valuable R&D asset stacks up against that of pharmaceutical giants.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Altimmune Inc.
Altimmune's balance sheet is its R&D capital. Its entire enormous market value is a premium for its weight-loss drug, which is one of the main competitors to Wegovy and Ozempic. The schedule is a bet on its ability to win share in this gigantic market.
Market to book capitalization ratio in a market segment - Pharma metabolism
Altimmune is a biotech company developing drugs to treat obesity and liver disease. Its high valuation on this chart reflects its participation in the "weight loss race," one of the hottest and most competitive areas in modern pharmaceuticals.
Market to book capitalization ratio for the market as a whole
Altimmune is a biotech company developing drugs to treat obesity and liver disease. Its market value fluctuates rapidly based on clinical trial results. This chart clearly shows how expectations for a single potential blockbuster impact the company's valuation.
Debts of the company, segment and market as a whole
ALT - Company debts Altimmune Inc.
Altimmune, a clinical-stage biotech developing drugs to treat obesity and liver disease, is using capital to fund its expensive trials. This chart shows how the company is raising funds to compete in one of the hottest markets in pharma, where success requires massive investments.
Market segment debts - Pharma metabolism
Altimmune is a clinical-stage biotech developing drugs to treat obesity and liver disease. This is a highly competitive and capital-intensive field. This chart shows how the company finances its expensive clinical trials, likely relying solely on equity capital, like its competitors.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Altimmune Inc.
Altimmune develops drugs for obesity and liver disease—huge and competitive markets. For such a company, debt is a way to accelerate clinical trials. This chart shows the financial stakes placed on the success of its drug candidates. It measures the risk, which increases as the company approaches the critical stages of research.
Market segment debt to market segment book capitalization - Pharma metabolism
Altimmune is developing drugs to treat obesity and liver disease, at the center of one of the hottest topics in modern pharmacology. Competition in this field is fierce. The chart shows how aggressively the biotech sector is using debt to fund expensive clinical trials, and how Altimmune stacks up in this race.
Debt to book value of all companies in the market
Altimmune, Inc., a biopharmaceutical company developing treatments for obesity and liver disease, requires significant investment in clinical trials. This chart, showing the market's overall debt load, helps us assess how its financial strategy is typical for biotech companies. It helps us understand how the company is funding its path to a potential blockbuster.
P/E of the company, segment and market as a whole
P/E - Altimmune Inc.
Altimmune is a clinical-stage biopharmaceutical company developing drugs to treat obesity and liver disease. This chart shows how the market values its developments. The company's valuation fluctuates dramatically based on clinical trial results, reflecting the enormous potential of the weight loss market.
P/E of the market segment - Pharma metabolism
Altimmune develops weight loss drugs in the hottest biotech market. This chart shows the average valuation for this sector. It emphasizes that Altimmune's valuation is entirely dependent on clinical trial data and its ability to compete with the giants, not on industry averages.
P/E of the market as a whole
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing treatments for obesity and liver disease, as well as immunomodulators. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether ALT's high valuation is based on the enormous potential of the obesity drug market or is driven by overall sentiment in the sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Altimmune Inc.
Altimmune is a biotech company developing drugs to treat obesity and liver disease. This chart reflects the high market expectations for its candidates amid the huge demand for effective weight loss treatments. It's a bet on the success of its clinical programs in one of the hottest areas of pharmaceuticals.
%20P%2FE%20Altimmune%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Altimmune-Inc.&v=1772626583498 "Chart of the company's future (projected) P/E Altimmune Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
Altimmune is a biotech company developing drugs for the treatment of obesity and liver disease, including the popular class of GLP-1 agonists. The data here reflects analysts' collective bets on the success of its clinical programs in one of the most competitive and hyped markets in modern pharmaceuticals.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772626583535 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Altimmune, a company developing drugs to treat obesity and liver disease, is at the forefront of the pharmaceutical industry's attention. This chart of overall market expectations shows how much investors are willing to pay for potential blockbusters. Market optimism is fueling high valuations for biotech companies in hot sectors.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772626583547 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Altimmune Inc.
Altimmune is a biotech company developing therapies for obesity and liver disease. This chart reflects the enormous interest and competition in this field. It shows the investment in clinical trials, the success of which could propel the company into the multi-billion dollar weight loss market.
Profit of companies in the market segment - Pharma metabolism
Altimmune is a clinical-stage biopharmaceutical company developing drugs for the treatment of obesity and liver disease. It is a player in one of the hottest markets in modern pharmaceuticals. Its future profitability depends on the results of clinical trials and its ability to compete with industry giants.
Overall market profit
Altimmune is a clinical-stage biotech developing drugs to treat obesity and liver disease. Its valuation depends on trial results. This market segment is highly competitive. The overall economic situation, reflected in this chart, influences investor sentiment and their willingness to fund companies in hot but risky sectors.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Altimmune Inc.
Altimmune is a biotech company developing drugs to treat obesity and liver disease. This chart reflects analysts' speculative expectations, which are heavily dependent on the clinical trial results of its lead candidate, pemvidutide, in the highly competitive weight loss drug market.
%20profit%20of%20the%20company%20Altimmune%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Altimmune-Inc.&v=1772626583624 "Graph of future (projected) profit of the company Altimmune Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Altimmune is a biotech company developing drugs to treat obesity and liver disease. The profitability forecasts for this sector, shown in the graph, demonstrate the enormous interest in new, effective weight loss treatments. This chart helps assess the competitiveness of Altimmune's candidate in this multi-billion dollar market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772626583648 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Altimmune is a biopharmaceutical company developing drugs for the treatment of obesity and liver disease. This market is one of the most promising, but also competitive. Success depends on trial results. Funding for such projects is easier to attract in an environment of market optimism, which accompanies the positive forecast in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772626583678 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Altimmune Inc.
Altimmune is a biotech company developing drugs to treat obesity and liver disease. While in the clinical stage, it may not generate revenue. This chart shows how highly investors value its potential, betting on the success of its drug candidates in the vast and competitive weight loss market.
P/S market segment - Pharma metabolism
Altimmune is a biopharmaceutical company developing drugs for the treatment of obesity and liver disease, including its lead candidate, pemvidutide. This chart shows the average revenue estimate for the biotech sector. It helps us understand the enormous market potential for the weight loss drugs the company is developing.
P/S of the market as a whole
Altimmune is a biopharmaceutical company developing treatments for obesity and liver disease. Its lead candidate competes with popular drugs such as Ozempic and Wegovy. This chart allows us to correlate the market's valuation of the companies with their actual revenues, which is important for contextualizing biotech analysis in this highly competitive niche.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Altimmune Inc.
Altimmune is a biotech company developing drugs to treat obesity and liver disease. This chart reflects investors' high valuation of its potential future revenue. This valuation is a direct bet on the success of its candidates in clinical trials in a highly competitive market.
%20P%2FS%20Altimmune%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Altimmune-Inc.&v=1772626583903 "The graph of the company's future (projected) P/S Altimmune Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
Altimmune is a clinical-stage biopharmaceutical company developing treatments for obesity and liver disease. This chart compares market expectations for its future revenue with other pharma companies in the metabolism field. The valuation reflects the high expectations of investors for its drug candidates in one of the most competitive areas of biotech.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772626583939 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Altimmune is a clinical-stage biotech developing drugs to treat obesity and liver disease. Its value has soared on expectations of success in this hot therapeutic area. This graph of overall market expectations is irrelevant for Altimmune; its fate hinges on the results of clinical trials, which could make it a multibillion-dollar company.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772626583954 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Altimmune Inc.
This chart shows the revenue of Altimmune, a clinical-stage biotech focused on treating obesity and liver disease. A lack of consistent commercial revenue is normal. Any revenue likely stems from partnerships. The chart emphasizes that the company's valuation depends on the results of clinical trials of its promising drugs.
Sales of companies in the market segment - Pharma metabolism
Altimmune is a biopharmaceutical company developing treatments for obesity and liver disease. Its lead candidate, pemvidutide, is aimed at competing in the rapidly growing GLP-1 agonist market. This chart shows revenue in the metabolism pharmaceutical sector. It reflects the explosive growth of the weight loss market, where Altimmune is seeking to capture a share.
Overall market sales
Altimmune is a biotech company developing drugs to treat obesity and liver disease. Its pricing is dependent on the results of clinical trials. Demand for obesity drugs is enormous and grows regardless of economic cycles, but overall economic growth, as shown in this chart, ensures the financial stability of the healthcare systems that will pay for them.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Altimmune Inc.
Altimmune is a clinical-stage biopharmaceutical company developing treatments for obesity and liver disease. This projected revenue chart reflects the tremendous excitement surrounding its weight-loss candidate. Its dynamics are entirely dependent on clinical trial expectations in one of the most competitive areas of modern pharmaceutical technology.
%20sales%20of%20the%20company%20Altimmune%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Altimmune-Inc.&v=1772626584124 "Schedule of future (projected) sales of the company Altimmune Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
Altimmune is a clinical-stage biopharmaceutical company developing drugs for the treatment of obesity and liver disease. Its lead candidate competes with popular weight-loss drugs. This chart shows projected revenues for the entire metabolism pharmaceutical sector, reflecting the enormous commercial potential of the obesity treatment market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772626584180 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Altimmune is a biotech company developing drugs to treat obesity and liver disease. This market is vast and rapidly growing. The company's success depends on the results of clinical trials. A positive economic environment is essential for attracting the significant investment needed to compete in this capital-intensive field.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772626584201 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Altimmune Inc.
Altimmune is a biotech company developing drugs to treat obesity and liver disease, two of the most competitive areas in pharmaceuticals. This chart reflects the high cost of entering this race. It shows the investment in clinical trials required to compete with industry giants.
Market segment marginality - Pharma metabolism
Altimmune is a clinical-stage biopharmaceutical company developing drugs for the treatment of obesity and liver disease. This chart compares its operating efficiency with other biotech companies. For a company whose core product is the focus of investors, profitability can fluctuate significantly depending on clinical trial costs.
Market marginality as a whole
Altimmune is a clinical-stage biotech company developing drugs to treat obesity and liver disease. Its success is independent of the general economic cycles shown in this chart. The company's value is determined solely by the results of clinical trials. Success in the vast weight-loss market could lead to exponential growth.
Employees in the company, segment and market as a whole
Number of employees in the company Altimmune Inc.
Altimmune is a clinical-stage biotech company developing drugs to treat obesity and liver disease. This chart shows the team working in one of the hottest sectors of biopharma. The growth in staff is directly related to progress in clinical trials and the high level of competition in this field.
Share of the company's employees Altimmune Inc. within the market segment - Pharma metabolism
Altimmune is a clinical-stage biotech company developing drugs for the treatment of obesity and liver disease. Its team is a focused group of scientists and clinicians. This graph reflects its current status: its small staff means the company is fully focused on conducting clinical trials for its promising candidates.
Number of employees in the market segment - Pharma metabolism
Altimmune develops drugs to treat obesity and liver disease, positioning itself at the center of one of the hottest areas in pharmaceuticals. This chart shows the competitive race to develop GLP-1 agonists. The dynamics of its small scientific team reflect the progress of clinical trials, where the company strives to create a drug capable of competing with products from the giants.
Number of employees in the market as a whole
Altimmune is a biopharmaceutical company developing drugs to treat obesity and liver diseases. Its growing workforce reflects progress in clinical trials, which requires hiring new specialists. This overall employment chart demonstrates that in biotech, growth is driven not by economics, but by scientific data and the potential of future blockbuster drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Altimmune Inc. (ALT)
Altimmune is a clinical-stage biopharmaceutical company developing drugs for obesity and liver disease, as well as an intranasal vaccine. This chart shows the enormous market value per scientist. This is a classic biotech scenario, where market capitalization is based on the potential of the company's development pipeline, not on current operations.
%20of%20the%20company%20Altimmune%20Inc.%20(ALT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Altimmune-Inc.-ALT&v=1772626584607 "Chart of market capitalization per employee (in thousands of dollars) of the company Altimmune Inc. (ALT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Altimmune is a biopharmaceutical company developing treatments for obesity and liver disease. In the highly competitive weight-loss drug space, this chart reflects market expectations. A high market capitalization per employee may indicate that investors believe in the potential of their drug candidates and their ability to compete with industry giants.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772626584639 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Altimmune is a clinical-stage biopharmaceutical company developing drugs to treat obesity and liver disease. This metric reflects how the market values a potential blockbuster. Their market capitalization has skyrocketed on anticipation of their drug, creating a huge valuation for each member of their small research team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772626584673 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Altimmune Inc. (ALT)
Altimmune is a clinical-stage biotech company known for its developments in obesity treatments (a competitor to Ozempic) and liver disease. They are not profitable. This chart shows their loss per employee. This is an indicator of the capital burn rate associated with expensive clinical trials of their potential blockbusters.
%20Chart%20Altimmune%20Inc.%20(ALT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Altimmune-Inc.-ALT&v=1772626584711 "Company Profit Per Employee (in thousands of dollars) Chart Altimmune Inc. (ALT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Altimmune is a biotech company developing treatments for obesity and liver disease, two of the hottest sectors in the pharmaceutical industry. The company has no profit, only R&D expenses. This metric reflects their capital burn rate per employee, which investors compare to industry norms.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772626584736 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Altimmune is a clinical-stage biotech company known for its developments in obesity and liver disease treatments. This chart doesn't show profits. It demonstrates massive investments in R&D: the negative per-employee ratio reflects the high cost of clinical trials and maintaining a team of scientists in this highly competitive field.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772626584745 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Altimmune Inc. (ALT)
Altimmune is a clinical-stage biopharmaceutical company developing drugs for the treatment of obesity and liver disease. This graph is typical for biotech in the hot sector. No revenue per employee is normal, as the company's entire value is concentrated in the potential of its drug candidates.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Altimmune-Inc.-ALT&v=1772626584786 "Sales chart per company employee Altimmune Inc. (ALT)")
Sales per employee in the market segment - Pharma metabolism
Altimmune (ALT) is a clinical-stage biotech focused on treating obesity (a GLP-1 competitor) and liver disease. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform in one of the hottest topics in pharma compared to other biotechs.
Sales per employee for the market as a whole
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of obesity (a GLP-1 competitor) and liver disease. This is an R&D business. The company has no commercial revenue. This metric is currently close to zero and does not reflect operating activities, but only research expenses.
Short shares by company, segment and market as a whole
Shares shorted by company Altimmune Inc. (ALT)
Altimmune is a biotech company attempting to enter the scorching weight loss drug (GLP-1) market. This chart reflects bearish bets. Bears believe Altimmune has no chance against giants Eli Lilly (Zepbound) and Novo Nordisk (Wegovy), whose drugs already dominate the market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Altimmune-Inc.-ALT&v=1772626584824 "Short Shares Chart for the Company Altimmune Inc. (ALT)")
Shares shorted by market segment - Pharma metabolism
Altimmune is a biotech company developing drugs for obesity (a competitor to Ozempic) and liver disease. This chart shows short bets. The "shorts" here are bets that their drug candidate (pemvidutide) will lose the weight-loss race to giants Lilly and Novo Nordisk.
Shares shorted by the overall market
Altimmune develops drugs to treat obesity and liver disease—some of the hottest topics in modern pharmacology. This chart measures overall market pessimism. Biotech stocks operating in hyped markets may attract a lot of attention, but how do they perform when the overall investment climate cools sharply and fear reigns?
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Altimmune Inc. (ALT)
Altimmune (ALT) is a biotech focused on treating obesity and liver disease. Their lead candidate, pemvidutide, competes with popular GLP-1 drugs (like Ozempic). It's a high-risk biotech. This chart measures hype. It shows when the stock is "overheated" (above 70) due to positive trial data or "oversold" (below 30) due to competitor failures or successes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Altimmune-Inc.-ALT&v=1772626584888 "RSI 14 indicator chart for the company's stock Altimmune Inc. (ALT)")
RSI 14 Market Segment - Pharma metabolism
Altimmune (ALT) is one of the hottest biotechs in the race for obesity drugs (GLP-1). The "Pharma Metabolism" sector is the epicenter of the hype. The RSI_14_Seg index for this segment is a barometer of overheating. It's vital to understand whether ALT's wild volatility is due to its R&D or whether the entire sector is simply overheated.
RSI 14 for the overall market
For Altimmune, a biotech company in the hot field of metabolism (obesity), this chart is a lifeline. During periods of market euphoria, investors are willing to "buy the dream" and generously fund expensive clinical trials. In moments of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALT (Altimmune Inc.)
Altimmune (ALT) is a biotech company developing drugs for the treatment of obesity (GLP-1 agonists) and liver disease. This chart shows the average target price. It reflects analysts' confidence in the potential of its lead candidate in the highly competitive weight loss market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALT-Altimmune-Inc.&v=1772626584990 "A chart showing analyst consensus forecasts for the expected stock price. ALT (Altimmune Inc.)")
The difference between the consensus estimate and the actual stock price ALT (Altimmune Inc.)
Altimmune is a biotech company that's betting all-in on the largest market in pharmaceuticals. They're developing their own drug (pemvidutide) to compete with giants like Ozempic and Mounjaro in the treatment of obesity. This chart shows how much analysts believe their candidate has a chance in this race of titans.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALT-Altimmune-Inc.&v=1772626585021 "A chart showing the difference between the consensus forecast and the actual stock price. ALT (Altimmune Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Altimmune is a biotech company that, following the setbacks of COVID and NASH, has focused on developing pemavidutide, its candidate for an "obesity drug" (GLP-1). This chart shows general expectations for the metabolism sector. It reflects whether experts believe another player will succeed in the hypercompetitive GLP-1 market.
Analysts' consensus forecast for the overall market share price
Altimmune (ALT) is a clinical-stage biopharmaceutical company. They rose to prominence by developing a drug to treat obesity (GLP-1), competing with giants Novo Nordisk and Eli Lilly. This chart shows the overall risk appetite, reflecting the market's willingness to fund the R&D race in the pharmaceutical industry's hottest topic.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Altimmune Inc.
Altimmune is a clinical-stage biotech company competing in the race to develop a drug for obesity (a Novo/Lilly competitor) and NASH (a liver disease). This chart is a pure R&D bet. It likely reflects the market's confidence in their clinical data (their drug, pemvidutide) and their chances of carving out a share of this gigantic but highly competitive market.
AKIMA Market Segment Index - Pharma metabolism
Altimmune (ALT) is a clinical-stage biotech focused on metabolic diseases; the company (like Viking) is developing its candidate (Pemvidutide) for the treatment of obesity and NASH/MASH (liver disease). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this highly competitive (GLP-1) R&D position (ALT) differentiate it from the average pharma?
The AKIM Index for the overall market
Altimmune is a biopharmaceutical company developing peptide drugs for the treatment of obesity and liver disease (MASH). It's a competitor in the incretin race. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this volatile company, which is seeking partners, fits into the context of overall economic trends.
